Physician profile

Philip S Fox

Psychiatry · Kentwood, MI

NPI 1013976596

$496.81

in general payments reported to CMS, 2019-2025

10 companies · $79.50 in 2025

The $79.50 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Education$79.50

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Sunovion Pharmaceuticals INC. $161.55 2019-2020
Teva Pharmaceuticals USA, INC. $79.50 2025
Takeda Pharmaceuticals U.S.A., INC. $50.72 2019
Lundbeck LLC $45.86 2019-2020
Allergan, INC. $43.29 2019-2020
Neurocrine Biosciences, INC. $41.34 2019-2020
Otsuka America Pharmaceutical, INC. $33.49 2019-2020
Janssen Pharmaceuticals, INC $16.38 2019
Shire North American Group INC $13.60 2019
Vanda Pharmaceuticals INC. $11.08 2020

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Philip S Fox

$496.81

in general payments reported 2019-2025

Years
2019-2025
Top company
Sunovion Pharmaceuticals INC.
Context
The $79.50 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).

https://glasscript.com/doctor/1016/philip-s-fox

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.